COVID-19 – Domainex response to the pandemic

At Domainex, the health, safety and wellbeing of every employee is our number one priority.

Find out more

  • Trevor Perrior, CEO, Domainex
    Our medicinal chemists believe that 'every compound counts' - Dr Trevor Perrior, CSO
    Every Compound Counts
  • Domainex is committed to the support of exciting and cutting-edge translational research
    Domainex is committed to the support of exciting and cutting-edge translational research
    Translational Research
  • Domainex applies unique technologies to overcome common drug discovery challenges
    Domainex applies unique technologies to overcome common drug discovery challenges
    Overcome Challenges
  • Domainex is developing an exciting pipeline of drugs that effect epigenetic targets
    Domainex is developing an exciting pipeline of drugs that effect epigenetic targets
    Exciting Pipeline

Current job opportunities

Message from Tom Mander, CEO of Domainex:

We are seeking applications from suitably qualified biologists (protein or assay scientists), chemists (analytical, computational or medicinal) and business developers.

We especially welcome applications from you if you have relevant industry experience, irrespective of your seniority.

These are exciting times to join us as we continue to invest in our people, facilities, R&D and commercial activities to continue the strong growth of our business.

We look forward to hearing from you!

View the job listings

Drug Discovery Services

Domainex is the fastest growing CRO in Europe.  By applying our novel proprietary technologies such as CDH and taking a focussed, integrated approach to medicinal chemistry, biochemistry and computational chemistry we can reduce your project timeline by up to 30%.
 

Read more

New technologies

Domainex has launched its new PoLiPa technology, which can purify any GPCR without the need for thermostabilising mutations or detergents by encapsulating it in a polymer along with a small disc of the native cell membrane lipids. PoLiPa-GPCRs are pharmacologically intact and very stable.

Read more

Technology

FragmentBuilder logo
FragmentBuilder:
Fragment screening using MicroScale Thermophoresis


Combinatorial Domain Hunting logo
Combinatorial Domain Hunting
: Protein expression and purification services.


BioassayBuilder logo
BioassayBuilder
: Bioassay services, assay development, HTS and compound testing services.


LeadBuilder logo
LeadBuilder
: Virtual hit screening platform.

Events

5th July to 6th July 2021
London, UK
29th August to 2nd September 2021
Basel, Switzerland